HOSPITAL UNIVERSITARIO RUBER

2024

1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

   The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

2. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

   Breast, Vol. 76

3. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

   Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

4. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

   Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

5. Adolescent Reference Values for MR-Derived Biventricular Strain Obtained Using Feature-Tracking and Myocardial Tagging

   Journal of Magnetic Resonance Imaging

6. AulaGinecología.com: A new educational tool in gynecology and obstetrics

   Educacion Medica, Vol. 25, Núm. 2

7. CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation

   Virchows Archiv

8. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

   ESMO Open, Vol. 9, Núm. 3

9. Clinico-pathological evaluation of tumor budding in the oncological progression of colorectal cancer

   Medicina Clinica

10. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

11. Confirmatory study of the usefulness of quantum molecular resonance and microdissectomy for the treatment of lumbar radiculopathy in a prospective cohort at 6 months follow-up

    Scandinavian Journal of Pain, Vol. 24, Núm. 1

12. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119

    Journal of Pathology: Clinical Research, Vol. 10, Núm. 3

13. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment, Vol. 205, Núm. 3, pp. 589-598

14. Developmental anatomy of the thalamus, perinatal lesions, and neurological development

    Developmental Medicine and Child Neurology

15. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

16. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

    Annals of Oncology, Vol. 35, Núm. 6, pp. 549-558

17. Endoscopically Assisted Intraoral Coronoidectomy for Treatment of Coronoid Hyperplasia

    Journal of Craniofacial Surgery, Vol. 35, Núm. 2, pp. 636-638

18. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology, Vol. 195

19. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

20. Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 7